Literature DB >> 1703032

Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives.

J Murata1, I Saiki, T Makabe, Y Tsuta, S Tokura, I Azuma.   

Abstract

The effect of antimetastatic sulfated chitin derivatives (SCM-chitin III) on angiogenesis induced by B16-BL6 cells was examined in syngeneic mice. SCM-chitin III caused a marked decrease of the number of vessels toward tumor mass (angiogenic response) without affecting the tumor cell growth when coinjected with tumor cells (on day 0), or injected into tumor site on day 1 or 3 after tumor inoculation. In contrast, carboxymethyl chitin as well as heparin had no effect. Invasion of endothelial cells through reconstituted basement membrane (Matrigel) toward tumor-conditioned media was significantly inhibited by SCM-chitin III in a Transwell chamber assay. SCM-chitin III also inhibited the haptotactic migration of endothelial cells to fibronectin-substrate, but did not inhibit the chemotactic activity in tumor conditioned media in vitro. SCM-chitin III did not directly affect the viability and the growth of tumor cells and endothelial cells in vitro. These results suggest that inhibition of lung tumor metastasis by SCM-chitin III may in part be due to the inhibition of tumor-associated angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1703032

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1996-06       Impact factor: 9.264

2.  Anti-Kaposi's sarcoma and antiangiogenic activities of sulfated dextrins.

Authors:  M Thornton; L Barkley; J C Mason; S Shaunak
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 3.  Antiangiogenesis as a novel therapeutic concept in pediatric oncology.

Authors:  L Schweigerer
Journal:  J Mol Med (Berl)       Date:  1995-10       Impact factor: 4.599

Review 4.  Vasculogenic mimicry and tumor angiogenesis.

Authors:  R Folberg; M J Hendrix; A J Maniotis
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

5.  Inhibition of tumor metastasis by Arg-Gly-Asp-Ser (RGDS) peptide conjugated with sulfated chitin derivative, SCM-chitin-RGDS.

Authors:  H Komazawa; I Saiki; N Nishikawa; J Yoneda; Y C Yoo; M Kojima; M Ono; I Itoh; N Nishi; S Tokura
Journal:  Clin Exp Metastasis       Date:  1993-11       Impact factor: 5.150

6.  Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis.

Authors:  T Mishima; J Murata; M Toyoshima; H Fujii; M Nakajima; T Hayashi; T Kato; I Saiki
Journal:  Clin Exp Metastasis       Date:  1998-08       Impact factor: 5.150

7.  DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice.

Authors:  Ayako Ojima; Takanori Matsui; Sayaka Maeda; Masayoshi Takeuchi; Hiroyoshi Inoue; Yuichiro Higashimoto; Sho-ichi Yamagishi
Journal:  Lab Invest       Date:  2014-02-10       Impact factor: 5.662

8.  beta-cyclodextrin tetradecasulfate/tetrahydrocortisol +/- minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma.

Authors:  B A Teicher; E A Sotomayor; Z D Huang; G Ara; S Holden; V Khandekar; Y N Chen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3.

Authors:  F J Candal; D C Bosse; W R Vogler; E W Ades
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.

Authors:  E A Sotomayor; B A Teicher; G N Schwartz; S A Holden; K Menon; T S Herman; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.